Please assess the completion status of the following clinical trial:

Trial Title: Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Patients with BN:~* Meets DSM-IV criteria for BN~* BN duration of more than 1 year~* Self-induces vomiting~* Weighs between 80 and 120% of ideal body weight~Exclusion Criteria for Patients with BN:~* Significant medical illness~* Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by DSM-IV-TR criteria~* Current DSM-IV-TR diagnosis of organic mental disorder, factitious disorder, or malingering~* History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with the study procedures~* At risk for suicide, as defined by the expression of an imminent plan or attempt within the 6 months prior to study entry~* Currently taking psychotropic medications or medications that affect gastrointestinal function~* Moderate to severe depression, as defined by a score of greater than 28 on the Hamilton Depression Rating Scale~* Drug or alcohol abuse within the 3 months prior to study entry~* Pregnant, planning to become pregnant, or lactating~* Body mass index (BMI) of less than 18 (underweight)~Inclusion Criteria for Normal Weight Controls:~* No current or past psychiatric history~* No history of binge eating or vomiting~* 80-120% of ideal body weight~Exclusion Criteria for Normal Weight Controls:~* Significant medical illness~* Current psychotropic medications and current medications that affect GI function~* Drug or alcohol abuse in last 3 months~* Pregnancy, planning to become pregnant or laction

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cholecystokinin (Type: EXPERIMENTAL): Participants will receive intravenous saline plus cholescystokinin.
- Saline (Type: PLACEBO_COMPARATOR): Participants will receive intravenous saline only.

Based on this trial design, predict the completion outcome and termination type (if applicable).